THIO is an investigational drug being studied for the treatment of advanced non-small cell lung cancer. It is designed to be used as part of a third-line treatment approach for patients whose cancer has progressed after previous treatments.

Cemiplimab (also known as LIBTAYO) is an immunotherapy medication that helps the body’s immune system recognize and fight cancer cells. It works by targeting and blocking a protein called PD-1, which can help the immune system better attack cancer cells.

Single-agent Chemotherapy refers to traditional cancer treatments that use one chemotherapy drug to kill cancer cells or stop them from growing. In this trial, the specific chemotherapy medication is chosen by the treating physician from available options.

Non-Small Cell Lung Cancer – A type of lung cancer that begins in the cells of the lungs and gradually forms tumors. It develops when healthy cells in the lung tissue begin to grow uncontrollably and form masses. The disease typically starts in the cells that line the airways of the lungs. It is characterized by the growth and spread of abnormal cells in the lung tissue, which can affect breathing and other bodily functions. The disease can progress from early stages where it is confined to the lungs to more advanced stages where it may spread to nearby tissues.